Wall Street analyst estimates for Kiora Pharmaceuticals, Inc. (KPRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials.
Valuation Ratios
| Price / Book | 0.99 |
| EV / EBITDA | -0.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $669259 | $407518 | $1.7M | $2.7M | $12059 | 0 | 0 | 0 | $16.0M | 0 |
| Cost of Revenue | $8.4M | $10.3M | $8.1M | $4889 | $3.3M | 0 | 0 | 0 | 0 | $24801 |
| Gross Profit | -$7.8M | -$9.9M | -$6.4M | $2.7M | -$3.3M | 0 | 0 | 0 | $16.0M | -$24801 |
| Research & Development | $8.4M | $10.3M | $8.1M | $5.4M | $3.6M | $5.4M | $3.4M | $4.0M | $4.9M | $10.8M |
| Selling, General & Admin | $5.6M | $4.6M | $4.4M | $4.4M | $4.2M | $5.3M | $8.3M | $4.7M | $5.5M | $5.7M |
| Operating Expenses | $14.0M | $15.0M | $12.5M | $9.8M | $3.6M | $14.2M | $12.3M | $12.6M | $11.5M | $9.4M |
| Operating Income | -$13.3M | -$14.6M | -$10.8M | -$7.0M | -$6.9M | -$14.2M | -$12.3M | -$12.6M | $4.5M | -$9.5M |
| EBITDA | -$13.3M | -$14.5M | -$10.7M | -$6.8M | -$7.5M | -$13.9M | -$13.6M | -$12.4M | $5.7M | -$12.1M |
| Interest Expense | $275 | $1215 | $1040 | $325 | $4186 | $6851 | $8599 | $11132 | $21446 | $19960 |
| Pre-tax Income | -$13.3M | -$14.6M | -$10.7M | -$7.0M | -$6.8M | -$14.0M | -$13.7M | -$12.4M | $5.7M | -$12.1M |
| Income Tax | $3684 | -$1.3M | $86045 | $95396 | $12055 | -$192603 | -$113010 | $90319 | $2.1M | -$1.3M |
| Net Income | -$13.3M | -$13.2M | -$10.8M | -$7.1M | -$6.9M | -$13.8M | -$13.6M | -$12.5M | $3.6M | -$10.8M |
| EPS | $-906.30 | $-556.17 | $-182.81 | $-89.24 | $-70.50 | $-68.00 | $-18.55 | $-24.25 | $0.93 | $-2.64 |
| EPS (Diluted) | $-906.30 | $-556.17 | $-182.81 | $-89.24 | $-70.50 | $-68.00 | $-18.55 | $-24.25 | $0.87 | $-2.64 |
| Shares Outstanding (Diluted) | $14723 | $23766 | $59139 | $79525 | $114787 | $241099 | $732303 | $538007 | $4.1M | $4.1M |
Price
| Price | $2.60 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of KPRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks